Abbott is the name behind many well-known products.

Abbott Laboratories (NYSE:ABT) agreed to acquire Exact Sciences for US$21b. The deal is set to reshape Abbott's diagnostics ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Quick Read Abbott Laboratories (ABT) raised its quarterly dividend to $0.63 with a 60.4% free cash flow payout ratio.

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval in Europe for its TactiFlex Duo ablation catheter to treat atrial ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

Abbott has delivered share price performance and passive income to investors for years. The company is diversified across healthcare businesses and sells many leading products. Abbott's performance ...